Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Technology ID
TAB-4239

ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage

E-Numbers
E-276-2014-0
Lead Inventors
Redon, Christophe
Co-Inventors
Zhang, Yiping
Bonner, William
Ji, Jiuping ("Jay")
Applications
Diagnostics
Therapeutic Areas
Oncology
Development Stages
Pre-clinical (in vivo)
Lead IC
NCI
ICs
NCI
Leidos

Summary:

The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.

Description of Technology:

Exposure to ionizing radiation or agents that induce DNA double-stranded breaks (DSBs) can result in severe damage to cell and/or tissues, including cell death. This can lead to illness (i.e., acute radiation syndrome, cancer, etc.) or even death.  Identifying the amount of exposure to a DNA DSB-causing agent can be useful in monitoring, determining the need for further testing, and avoidance or modification of certain medical interventions and/or types of medical treatments. DNA damage caused by DSBs can be identified and quantified in situ by detecting phosphorylated histone protein γ-H2AX (gamma-H2AX) foci which is formed at DSBs. However, existing methods of analyzing γ-H2AX are laborious, low-throughput, and prone to variability.

Investigators in NCI’s Developmental Therapeutics Branch have developed a novel, high-throughput ELISA-based biodosimeter to measure DNA damage. This biodosimeter simultaneously quantifies the amount of γ-H2AX and total H2AX and results in a percent γ-H2AX, which is a normalized value representative of the amount of DNA damage. Overall, this biodosimeter provides users with flexibility of input sample type (ex. cells, tissues, blood) and high-throughput, less laborious option to precisely measure DNA damage. It provides reliable, dose-dependent measurement outputs that are independent of variability in cell number, cell viability, cell lysis efficiency, and laboratory operator. Additionally, the biodosimeter is both sensitive and specific, having a 100-fold quantitative range with sensitivity of 5 pM for γ-H2AX and 50 pM for H2AX.

NCI is seeking co-development partners and/or licensees to further develop this novel ELISA-based biodosimeter.

Potential Commercial Applications:

  • Assay for measuring DNA damage by a variety of causes (ex. ionizing radiation, environmental agents, chemotherapeutic agents, etc.)
  • Biodosimeter to monitor cancer drug treatment course
  • High-throughput screening of new drugs targeting DNA metabolism

Competitive Advantages:

  • Quantitative
  • High sensitivity and selectivity
  • Can be used on varying sample types (ex. cells, blood, and or tissues)
  • Has internal controls for reliable measurements
  • High-throughput and less laborious than other methods for assaying γH2AX levels
Licensing Contacts
McCrary, Michaela
michaela.mccrary@nih.gov